Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker

Journal of Urology

Volumn 182, Issue 1, 2009, Pages 52-58

  Lotan, Yair ^a   Elias, Keren ^a   Svatek, Robert S ^a   Bagrodia, Aditya ^a   Nuss, Geoffrey ^a   Moran, Brett ^a   Sagalowsky, Arthur I ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

mass screening; nuclear matrix protein 22; urinary bladder neoplasms

Indexed keywords

NUCLEAR MATRIX PROTEIN 22;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CANCER SCREENING; CANCER STAGING; CIGARETTE SMOKING; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC KIT; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; POINT OF CARE TESTING; PRIORITY JOURNAL; URINALYSIS; URINE CYTOLOGY;

AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NUCLEAR PROTEINS; POINT-OF-CARE SYSTEMS; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SEX FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 67349138615     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.02.142     Document Type: Article

References (25)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71
2. American College of Surgeons. Commission on Cancer National Cancer Database. http://www.facs.org/cancer/ncdb/index.html Accessed September 7, 2005
3. Zeegers M.P., Tan F.E., Dorant E., and van DenBrandt P.A. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89 (2000) 630
4. Silverman D.T., Hartge P., Morrison A.S., and Devesa S.S. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 6 (1992) 1
5. Messing E.M., Young T.B., Hunt V.B., Gilchrist K.W., Newton M.A., Bram L.L., et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45 (1995) 387
6. Messing E.M., Madeb R., Young T., Gilchrist K.W., Bram L., Greenberg E.B., et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107 (2006) 2173
7. Messing E.M., and Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med 32 (1990) 838
8. Britton J.P., Dowell A.C., Whelan P., and Harris C.M. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 148 (1992) 788
9. Lotan Y., and Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61 (2003) 109
10. Grossman H.B., Messing E., Soloway M., Tomera K., Katz G., Berger Y., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 (2005) 810
11. Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G., et al. American Joint Commitee on Cancer (AJCC) Staging Manual. 6th ed. (2002), Springer, Philadelphia
12. Epstein J.I., Amin M.B., Reuter V.R., and Mostofi F.K. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22 (1998) 1435
13. Marsh G.M., and Cassidy L.D. The Drake Health Registry Study: findings from fifteen years of continuous bladder cancer screening. Am J Ind Med 43 (2003) 142
14. Bi W., Hayes R.B., Feng P., Qi Y., You X., Zhen J., et al. Mortality and incidence of bladder cancer in benzidine-exposed workers in China. Am J Ind Med 21 (1992) 481
15. Hemstreet III G.P., Yin S., Ma Z., Bonner R.B., Bi W., Rao J.Y., et al. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 93 (2001) 427
16. Hedelin H., Jonsson K., Salomonsson K., and Boman H. Screening for bladder tumours in men aged 60-70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy. Scand J Urol Nephrol 40 (2006) 26
17. Marshall V.F. Current clinical problems regarding bladder tumors. Cancer 9 (1956) 543
18. Surveillance, Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.
19. Silverman D.T., Alguacil J., Rothman N., Real F.X., Garcia-Closas M., Cantor K.P., et al. Does increased urination frequency protect against bladder cancer?. Int J Cancer 123 (2008) 1644
20. Henschke C.I., Yankelevitz D.F., Libby D.M., Pasmantier M.W., Smith J.P., and Miettinen O.S. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355 (2006) 1763
21. Sone S., Nakayama T., Honda T., Tsushima K., Li F., Haniuda M., et al. Long-term follow-up study of a population-based 1996-1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography. Lung Cancer 58 (2007) 329
22. Weissfeld J.L., Schoen R.E., Pinsky P.F., Bresalier R.S., Church T., Yurgalevitch S., et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst 97 (2005) 989
23. Steiner H., Bergmeister M., Verdorfer I., Granig T., Mikuz G., Bartsch G., et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int 102 (2008) 291
24. Sarosdy M.F., Kahn P.R., Ziffer M.D., Love W.R., Barkin J., Abara E.O., et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176 (2006) 44
25. Lotan Y., Svatek R.S., and Sagalowsky A.I. Should we screen for bladder cancer in a high-risk population?: a cost per life-year saved analysis. Cancer 107 (2006) 982